Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 AbsenceOfExposureDefinition
.... 14.2 Adaptation
.... 14.3 BaselineMeasureEvidence
.... 14.4 BaselineMeasureReport
.... 14.5 BaselineVariablesList
.... 14.6 BookCitation
.... 14.7 BookPartCitation
.... 14.8 CertaintyOfEvidence
.... 14.9 Classification
.... 14.10 CohortDefinition
.... 14.11 Comment
.... 14.12 ComparativeBaselineMeasureEvidence
.... 14.13 ComparativeEvidence
.... 14.14 ComparativeEvidenceReport
.... 14.15 ComparativeEvidenceReportExpanded
.... 14.16 ComparativeEvidenceReportSubject
.... 14.17 ComparativeEvidenceSynthesisReport
.... 14.18 ComparativeParticipantFlowEvidence
.... 14.19 ComparatorGroup
.... 14.20 ComparatorOnlyEvidence
.... 14.21 Comparison
.... 14.22 CompositeRating
.... 14.23 ConceptualCohortDefinition
.... 14.24 ConceptualComparatorDefinition
.... 14.25 ConceptualExposureDefinition
.... 14.26 DatabaseCitation
.... 14.27 DatabaseEntryCitation
.... 14.28 DatasetCitation
.... 14.29 DateAsRating
.... 14.30 DichotomousIntendedOutcome
.... 14.31 EndpointAnalysisPlan
.... 14.32 EvidenceAssessment
.... 14.33 EvidenceList
.... 14.34 EvidenceReport
.... 14.35 EvidenceReportPackage
.... 14.36 EvidenceReportSubject
.... 14.37 EvidenceSynthesisEvidence
.... 14.38 ExposureGroup
.... 14.39 GroupAssignment
.... 14.40 GroupR6
.... 14.41 Guideline
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReasonEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 ParticipantFlowVariablesList
.... 14.63 PreprintCitation
.... 14.64 Rating
.... 14.65 Recommendation
.... 14.66 RecommendationAction
.... 14.67 RecommendationEligibilityCriteria
.... 14.68 RecommendationJustification
.... 14.69 RecommendationPlan
.... 14.70 RecommendationRating
.... 14.71 ResearchStudyDataDictionary
.... 14.72 ResearchStudySite
.... 14.73 ResearchStudySupport
.... 14.74 RiskOfBias
.... 14.75 SearchResults
.... 14.76 SearchStrategy
.... 14.77 SingleStudyEvidence
.... 14.78 SoaPlanDefinition
.... 14.79 SoftwareCitation
.... 14.80 StatisticModel
.... 14.81 StudyComponent
.... 14.82 StudyDesign
.... 14.83 StudyEligibilityCriteria
.... 14.84 StudyGroup
.... 14.85 StudyRegistryRecord
.... 14.86 SummaryOfFindings
.... 14.87 SummaryOfNetEffect
.... 14.88 SystematicReview
.... 14.89 SystematicReviewEligibilityCriteria
.... 14.90 SystematicReviewExcludedStudies
.... 14.91 SystematicReviewIncludedStudies
.... 14.92 VariableDefinition
.... 14.93 WebPageCitation
.... 14.94 ArtifactAssessmentCompared
.... 14.95 ArtifactAssessmentDateAsRating
.... 14.96 ArtifactPublicationStatus
.... 14.97 ArtifactRecorder
.... 14.98 CharacteristicTiming
.... 14.99 CiteAs
.... 14.100 EvidenceVariableHandlingDetail
.... 14.101 GuidelineRegistration
.... 14.102 NumberAnalyzed
.... 14.103 RelatesTo
.... 14.104 RelatesToClassifier
.... 14.105 RelatesToWithQuotation
.... 14.106 RelativeOutcomeImportance
.... 14.107 ResearchStudyExcludedStudy
.... 14.108 ResearchStudyIncludedStudy
.... 14.109 ResearchStudyIsLowInterventionTrial
.... 14.110 ResearchStudyIsRareDisease
.... 14.111 ResearchStudyNumberOfStudiesIdentified
.... 14.112 ResearchStudyNumberOfStudiesIncluded
.... 14.113 ResearchStudySaeReportingMethod
.... 14.114 ResearchStudySearchStrategy
.... 14.115 ResearchStudySponsorConfidentialityStatement
.... 14.116 ResearchStudyStudyAmendment
.... 14.117 ResearchStudySystematicReviewEligibilityCriteria
.... 14.118 StatisticModelExpression
.... 14.119 StatisticModelIncludeIf
.... 14.120 Desirability Codes Value Set
.... 14.121 EBMonFHIR Profile Name Value Set
.... 14.122 Evidence Rating System Classifier Codes Value Set
.... 14.123 Recommendation Justification Classifier Codes Value Set
.... 14.124 Research Study Document Types Value Set
.... 14.125 ResearchStudy Classifier Value Set
.... 14.126 Search Strategy Characteristic Value Set
.... 14.127 Desirability Code System
.... 14.128 EBMonFHIR Profile Name Code System
.... 14.129 Evidence Rating System Classifier Code System
.... 14.130 Research Study Document Types Code System
.... 14.131 Search Strategy Characteristic Code System
.... 14.132 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.133 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.134 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.135 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.136 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.137 179899
.... 14.138 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.139 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.140 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.141 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.142 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.143 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.144 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.145 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.146 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.147 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.148 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.149 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.150 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.151 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.152 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.153 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.154 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.155 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.156 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.157 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.158 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.159 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.160 27979893 6. Glycemic Targets.
.... 14.161 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.162 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.163 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.164 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.165 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.166 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.167 30467172 Finding my inner Wonder Woman.
.... 14.168 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.169 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.170 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.171 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.172 367832
.... 14.173 367833
.... 14.174 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.175 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.176 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.177 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 14.178 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.179 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.180 Add-on Amlodipine at 6 weeks
.... 14.181 Adults with diabetes mellitus type 2
.... 14.182 Adults with type 2 diabetes and CVD and CKD
.... 14.183 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.184 Adverse event free and hypertension control
.... 14.185 Adverse event free and hypertension control at 12 weeks
.... 14.186 Adverse Events Report for NCT03421379
.... 14.187 Adverse Events Report for NCT03640312
.... 14.188 Age
.... 14.189 Age with comparator
.... 14.190 Age with intervention
.... 14.191 Aircraft Type
.... 14.192 Aircraft Type with comparator
.... 14.193 Aircraft Type with intervention
.... 14.194 Altitude
.... 14.195 Altitude comparing intervention vs. comparator
.... 14.196 Altitude for enrolled group
.... 14.197 Altitude for screened group
.... 14.198 Altitude with comparator
.... 14.199 Altitude with intervention
.... 14.200 Analyzed Group in PARACHUTE Trial
.... 14.201 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.202 Baseline Characteristics Report for NCT03421379
.... 14.203 Baseline Characteristics Report for NCT03640312
.... 14.204 Baseline Characteristics Report for QUARTET Trial
.... 14.205 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.206 Baseline Measures List for PARACHUTE Trial
.... 14.207 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.208 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.209 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.210 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.211 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.212 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.213 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.214 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.215 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.216 Candesartan 8 mg once daily
.... 14.217 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.218 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.219 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.220 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.221 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.222 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.223 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.224 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.225 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.226 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.227 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.228 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.229 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.230 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.231 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.232 Citation for EBMonFHIR Implementation Guide
.... 14.233 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.234 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.235 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.236 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.237 Comparative Evidence Report for QUARTET USA Trial
.... 14.238 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.239 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.240 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.241 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.242 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.243 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.244 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.245 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.246 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.254 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.255 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.256 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.257 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.258 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.259 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.260 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.261 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.262 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.263 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.264 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.265 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.266 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.267 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.268 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.269 ComparatorDefinition: Standard care
.... 14.270 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.271 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.272 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.273 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.274 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.275 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.276 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.277 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.278 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.279 Computable_Publishing_LLC
.... 14.280 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.281 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.282 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.283 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.284 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.285 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.286 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.287 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.288 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.289 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.290 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.291 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.292 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.293 ConceptualCohortDefinition: Nonfatal stroke
.... 14.294 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 14.295 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.296 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.297 ConceptualCohortDefinition: Severe obesity
.... 14.298 ConceptualCohortDefinition: T1DM or T2DM
.... 14.299 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.300 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.301 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.302 ConceptualCohortDefinition_Cardiovascular_event
.... 14.303 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.304 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.305 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.306 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.307 COVID_19PneumoniaHospitalizedAdult
.... 14.308 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.309 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.310 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.311 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.312 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.313 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.314 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.315 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.316 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.317 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.318 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.319 DatabaseCitation: Citation for FEvIR Platform
.... 14.320 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.321 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.322 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.323 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.324 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.325 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.326 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.327 declined randomization in PARACHUTE Study
.... 14.328 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.329 Delany-Moretlwe 2022 clinical trial
.... 14.330 Diabetes treatment medication
.... 14.331 Diastolic blood pressure at 12 weeks
.... 14.332 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 14.333 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.334 DichotomousIntendedOutcome: New onset depression
.... 14.335 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 14.336 DichotomousIntendedOutcome: Remission of diabetes
.... 14.337 DichotomousIntendedOutcome: Treatment with opioids
.... 14.338 DIO: Mortality
.... 14.339 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.340 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.341 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.342 Eligibility criteria for NMA_Diabetes
.... 14.343 Eligibility Criteria for QUARTET USA Trial
.... 14.344 Enrolled Group for QUARTET USA Trial
.... 14.345 Enrolled Group PARACHUTE Trial
.... 14.346 Ethnic Group
.... 14.347 Ethnic Group with comparator
.... 14.348 Ethnic Group with intervention
.... 14.349 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.350 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.351 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.352 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.353 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.354 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.355 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.356 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.357 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.358 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.359 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.360 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.361 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.362 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.363 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.364 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.365 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.366 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.367 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.368 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.369 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.370 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.371 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.372 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.373 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.374 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.375 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.376 EvidenceReportSectionCode Value Set
.... 14.377 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.378 EvidenceVariable Handling Extension Value Set
.... 14.379 EvidenceVariable: case_id
.... 14.380 EvidenceVariable: Patient id
.... 14.381 EvidenceVariable: Time of measurement
.... 14.382 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.383 Excluded from PARACHUTE Study
.... 14.384 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.385 ExposureVariable: Age (as continuous variable)
.... 14.386 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.387 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.388 ExposureVariable: pht013093.v1.p1 RACE
.... 14.389 ExposureVariable: pht013093.v1.p1 SEX
.... 14.390 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.391 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.392 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.393 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.394 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.395 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.396 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.397 Family History of Parachute Use
.... 14.398 Family History of Parachute Use with comparator
.... 14.399 Family History of Parachute Use with intervention
.... 14.400 Frequent Flier
.... 14.401 Frequent Flier with comparator
.... 14.402 Frequent Flier with intervention
.... 14.403 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.404 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 14.405 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.406 Glucagon Nasal Powder (Experimental)
.... 14.407 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.408 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.409 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.410 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.411 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.412 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.413 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.414 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.415 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.416 GroupAssignment: Quadpill vs. Candesartan
.... 14.417 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.418 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.419 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.420 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.421 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.422 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.423 Health Survey Score Total
.... 14.424 Health Survey Score Total comparing intervention vs. comparator
.... 14.425 Health Survey Score Total with comparator
.... 14.426 Health Survey Score Total with intervention
.... 14.427 Health Survey Score-Mental Health Subscore
.... 14.428 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.429 Health Survey Score-Mental Health Subscore with comparator
.... 14.430 Health Survey Score-Mental Health Subscore with intervention
.... 14.431 Health Survey Score-Physical Health Subscore
.... 14.432 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.433 Health Survey Score-Physical Health Subscore with comparator
.... 14.434 Health Survey Score-Physical Health Subscore with intervention
.... 14.435 Health-related Quality of Life (NCT03640312)
.... 14.436 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.437 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.438 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.439 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.440 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.441 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.442 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.443 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.444 Height
.... 14.445 Height with comparator
.... 14.446 Height with intervention
.... 14.447 High Blood Pressure Medication Value Set
.... 14.448 History of Acrophobia
.... 14.449 History of Acrophobia with comparator
.... 14.450 History of Acrophobia with intervention
.... 14.451 History of Broken Bones
.... 14.452 History of Broken Bones with comparator
.... 14.453 History of Broken Bones with intervention
.... 14.454 History of Parachute Use
.... 14.455 History of Parachute Use with comparator
.... 14.456 History of Parachute Use with intervention
.... 14.457 Hypertension Control at 12 weeks
.... 14.458 ICD-10-GM Terminale Codes
.... 14.459 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.460 Injury Severity Score 30 days after Impact with comparator
.... 14.461 Injury Severity Score 30 days after Impact with intervention
.... 14.462 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.463 Injury Severity Score on Impact with comparator
.... 14.464 Injury Severity Score on Impact with intervention
.... 14.465 International vs Domestic Flight
.... 14.466 International vs Domestic Flight with comparator
.... 14.467 International vs Domestic Flight with intervention
.... 14.468 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.469 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.470 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.471 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.472 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.473 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.474 Investigator
.... 14.475 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.476 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.477 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.478 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.479 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.480 Jumping from aircraft with empty backpack
.... 14.481 Jumping from aircraft with parachute
.... 14.482 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.483 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.484 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.485 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.486 M11 Report Template Instructions
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.495 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.497 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.498 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.499 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.500 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.501 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.502 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.504 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.505 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.506 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.507 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.508 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.509 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.510 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.511 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.512 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.513 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.514 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.515 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.516 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.517 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.518 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.519 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.520 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.521 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.522 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.523 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.524 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.525 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.526 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.527 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.528 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.529 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.530 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.531 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.532 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.538 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.539 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.540 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.541 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.542 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.543 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.544 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.545 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.546 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.547 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.548 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.549 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.550 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.551 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.552 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.553 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.554 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.555 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.556 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.557 Mean Change in Serum Creatinine (NCT03640312)
.... 14.558 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.559 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.560 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.561 Mean Change in Serum Potassium (NCT03640312)
.... 14.562 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.563 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.564 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.565 Mean Change in Serum Sodium (NCT03640312)
.... 14.566 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.567 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.568 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.569 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.570 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.571 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.572 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.573 Mean Systolic Blood Pressure (NCT03640312)
.... 14.574 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.575 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.576 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.577 Median Age of Parachute Intervention Group
.... 14.578 Medication Adherence (NCT03640312)
.... 14.579 Medication Adherence at 12 weeks
.... 14.580 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.581 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.582 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.583 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.584 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.585 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.586 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.587 Mortality at 14 days
.... 14.588 NCT03421379 Eligibility Criteria
.... 14.589 NCT03640312 Eligibility Criteria
.... 14.590 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.591 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.592 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.593 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.594 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.595 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.596 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.597 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.598 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.599 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.600 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.601 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.602 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.603 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.604 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.605 NHANES SEQN Respondent Sequence Number
.... 14.606 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.607 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.608 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.609 NT-proBNP Study Data Dictionary
.... 14.610 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.611 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.612 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.613 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.614 Organ support-free days
.... 14.615 Outcome Importance Rating 100 of All-cause mortality
.... 14.616 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.617 Outcome Importance Rating 5 of New onset depression
.... 14.618 Outcome Importance Rating 5 of Remission of diabetes
.... 14.619 Outcome Importance Rating 5 of Treatment with opioids
.... 14.620 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.621 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.622 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.623 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.624 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.625 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.626 Outcome Importance Rating of DIO: Mortality for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 14.627 Outcome Measure List for QUARTET USA Trial
.... 14.628 Outcome Measure Report for QUARTET USA Trial
.... 14.629 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.630 Outcome Measures Report for NCT03421379
.... 14.631 Outcome Measures Report for NCT03640312
.... 14.632 Outcome Variables List for PARACHUTE Trial
.... 14.633 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.634 Outcome: Death or Major Traumatic Injury on Impact
.... 14.635 Outcome: Injury Severity Score 30 days after Impact
.... 14.636 Outcome: Injury Severity Score on Impact
.... 14.637 OutcomeDefinition: Injury Severity Score on Impact
.... 14.638 OutcomeDefinition: All-cause mortality
.... 14.639 OutcomeDefinition: All-cause mortality
.... 14.640 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.641 OutcomeDefinition: Body weight
.... 14.642 OutcomeDefinition: Body weight
.... 14.643 OutcomeDefinition: Cardiovascular mortality
.... 14.644 OutcomeDefinition: Cardiovascular mortality
.... 14.645 OutcomeDefinition: Diabetes in remission
.... 14.646 OutcomeDefinition: Diabetic ketoacidosis
.... 14.647 OutcomeDefinition: End-stage kidney disease
.... 14.648 OutcomeDefinition: End-stage kidney disease
.... 14.649 OutcomeDefinition: Genital infection
.... 14.650 OutcomeDefinition: HbA1c at 12 months
.... 14.651 OutcomeDefinition: HbA1c at 24 months
.... 14.652 OutcomeDefinition: HbA1c at 36 months
.... 14.653 OutcomeDefinition: HbA1c at 6 months
.... 14.654 OutcomeDefinition: HbA1c at 60 months
.... 14.655 OutcomeDefinition: Health-related quality of life
.... 14.656 OutcomeDefinition: Health-related quality of life
.... 14.657 OutcomeDefinition: Heart failure
.... 14.658 OutcomeDefinition: Heart failure
.... 14.659 OutcomeDefinition: Mortality at 14 days
.... 14.660 OutcomeDefinition: New onset depression
.... 14.661 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.662 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.663 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.664 OutcomeDefinition: Nonfatal stroke
.... 14.665 OutcomeDefinition: Nonfatal stroke
.... 14.666 OutcomeDefinition: Serious hyperglycaemia
.... 14.667 OutcomeDefinition: Serious hyperglycaemia
.... 14.668 OutcomeDefinition: Severe gastrointestinal events
.... 14.669 OutcomeDefinition: Severe gastrointestinal events
.... 14.670 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.671 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.672 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.673 OutcomeVariable: HbA1c at 12 months
.... 14.674 OutcomeVariable: HbA1c at 24 months
.... 14.675 OutcomeVariable: HbA1c at 36 months
.... 14.676 OutcomeVariable: HbA1c at 6 months
.... 14.677 OutcomeVariable: HbA1c at 60 months
.... 14.678 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.679 OutcomeVariable: New onset depression
.... 14.680 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.681 OutcomeVariable: Remission of diabetes
.... 14.682 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.683 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.684 OutcomeVariable_All_cause_mortality
.... 14.685 OutcomeVariable_Treatment_with_opioids
.... 14.686 PARACHUTE Trial baseline characteristics
.... 14.687 PARACHUTE Trial non participants
.... 14.688 PARACHUTE trial participant flow report
.... 14.689 PARACHUTE Trial Participants
.... 14.690 PARACHUTE Trial Participants assigned an empty backpack
.... 14.691 PARACHUTE trial participants assigned parachute
.... 14.692 PARACHUTE Trial Participants available for randomization
.... 14.693 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.694 PARACHUTE Trial Participants randomized into groups
.... 14.695 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.696 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.697 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.698 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.699 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.700 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.701 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.702 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.703 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.704 PARACHUTE Trial Participants that declined randomization
.... 14.705 PARACHUTE Trial Participants with no contact at 30 days
.... 14.706 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.707 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.708 PARACHUTE Trial Results
.... 14.709 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.710 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.711 Participant Flow Report for NCT03421379
.... 14.712 Participant Flow Report for NCT03640312
.... 14.713 Participant Flow Report for QUARTET USA Trial
.... 14.714 Participant Flow Variables List for PARACHUTE Trial
.... 14.715 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.716 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.717 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.718 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.719 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.720 ParticipantFlowMeasure: Exclusion from analysis
.... 14.721 ParticipantFlowMeasure: Inclusion in analysis
.... 14.722 Participants Excluded from PARACHUTE Study
.... 14.723 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.724 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.725 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.726 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.727 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.728 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 14.729 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.730 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.731 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 14.732 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.733 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.734 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.735 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.736 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.737 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.738 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.739 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.740 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 14.741 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.742 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.743 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.744 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.745 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.746 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.747 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.748 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.749 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.750 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.751 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.752 Placebo
.... 14.753 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.754 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.755 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.756 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.757 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.758 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.759 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.760 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.761 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.762 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.763 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.764 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.765 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.766 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.767 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.768 Quadpill once daily
.... 14.769 QUARTET USA Trial Control Group
.... 14.770 QUARTET USA Trial Quadpill group
.... 14.771 randomized into groups for PARACHUTE Trial
.... 14.772 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.773 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.774 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.775 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.776 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.777 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.778 Reasons for exclusion from QUARTET USA Trial
.... 14.779 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.780 Recommendation Justification Code System
.... 14.781 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.782 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.783 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.784 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.785 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.786 Remdesivir
.... 14.787 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.788 ResearchStudy Classifier Code System
.... 14.789 Results Section for NCT03421379
.... 14.790 Results Section for NCT03640312
.... 14.791 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.792 Risk of Bias Assessment of PARACHUTE trial
.... 14.793 Risk Of Bias Type Value Set
.... 14.794 Screened Group PARACHUTE Trial
.... 14.795 Search Strategy for NMA_Diabetes
.... 14.796 SearchResults: PubMed search for Wonder Woman
.... 14.797 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.798 SearchStrategy: PubMed search for Wonder Woman
.... 14.799 Sex
.... 14.800 Sex with comparator
.... 14.801 Sex with intervention
.... 14.802 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.803 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.804 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.805 Spanish or English Value Set
.... 14.806 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.807 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.808 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.809 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.810 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.811 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.812 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.813 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.814 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.815 Summary of Findings - QUARTET USA Trial
.... 14.816 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.817 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.818 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.819 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.820 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.821 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.822 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.823 Systolic blood pressure at 12 weeks
.... 14.824 Time to integration of results in a recommendation
.... 14.825 VariableDefinition: Comparator
.... 14.826 VariableDefinition: Condition(s)
.... 14.827 VariableDefinition: Date of birth
.... 14.828 VariableDefinition: Date of measurement
.... 14.829 VariableDefinition: Gender
.... 14.830 VariableDefinition: NTproBNP
.... 14.831 VariableDefinition: Unit
.... 14.832 Velocity
.... 14.833 Velocity comparing intervention vs. comparator
.... 14.834 Velocity for enrolled group
.... 14.835 Velocity for non participant group
.... 14.836 Velocity with comparator
.... 14.837 Velocity with intervention
.... 14.838 WebPageCitation: A HEvKA Update Summary
.... 14.839 Weight
.... 14.840 Weight with comparator
.... 14.841 Weight with intervention